<DOC>
	<DOCNO>NCT00630110</DOCNO>
	<brief_summary>This clinical trial examine vascular disrupt agent NPI-2358 combine docetaxel patient advance non-small cell lung cancer ( NSCLC ) . The formation new blood vessel ( angiogenesis ) important component tumor growth , vascular disrupt agent intend target difference tumor blood vessel blood vessel normal tissue .</brief_summary>
	<brief_title>Phase 1/2 Study Vascular Disrupting Agent NPI-2358 + Docetaxel Patients With Advanced Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>This clinical trial examine vascular disrupt agent NPI-2358 combine docetaxel patient advance non-small cell lung cancer ( NSCLC ) . The formation new blood vessel ( angiogenesis ) important component tumor growth , vascular disrupt agent intend target difference tumor blood vessel blood vessel normal tissue . There indication advantage combine vascular disrupt agent standard agent treatment advance non-small cell lung cancer ( NSCLC ) .</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Diketopiperazines</mesh_term>
	<criteria>Male female ≥ 18 year age ECOG performance status ≤ 1 Pathologically histologically confirm advanced nonsmall cell lung cancer ( unresectable Stage IIIb IV ) progress treatment least one chemotherapy regimen ; measurable disease require enrollment trial All Adverse Events prior chemotherapy , surgery , radiotherapy , must resolve Grade ≤ 2 Signed inform consent Administration certain chemotherapy , biological , immunotherapy , radiation therapy , surgery investigational agent within specified time frame Significant cardiac history Prior treatment tumor vascular disruptive agent Seizure disorder Brain metastasis Active uncontrolled bacterial , viral , fungal infection , require systemic therapy Known infection human immunodeficiency virus ( HIV ) , active hepatitis A , B , C Patients prior hypersensitivity reaction product component Pregnant breastfeeding woman . Concurrent , active second malignancy patient receive therapy , exclude basal cell carcinoma skin carcinoma situ cervix Unwilling unable comply procedure require protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>Non Small Cell Lung</keyword>
</DOC>